Today's Date: June 12, 2024
Statement by the Minister of Labour on World Day Against Child Labour   •   The American Warrior Association Receives City of Fort Worth Proclamation Marking June 11 as Moral Injury Awareness Day   •   The Best of The Southwest Luxury Lifestyle Magazine Debuts   •   Statement by the Minister of Labour on World Day Against Child Labour   •   SBS Entertainment, La Musica and Mega 96.3FM's Summer Spotlight Series is back for its second year featuring live music performa   •   PCI to Open State-of-the-Art Presort Mailing Facility in Indianapolis, Generating Nearly 100 Jobs   •   The Benefits Are On The Balance Sheet: Corporate America Must Stand By DEI And Chief Diversity Officers   •   Global Brain and Vision Research Nonprofit to Host Inaugural Concert for Cures Celebrating Science   •   “Golden Eight” Collection of Signed Michael Phelps Paintings Unveiled for the First Time Ahead of 2024 Summer Olympi   •   Matthew Carnes, S.J., Named Vice President for Mission and Ministry at Santa Clara University   •   Hong Kong Tourism Board and Art Basel Announce Three-Year Global Partnership   •   Grayce Raises $10.4M Series A for Family Care Solution, Scaling Social Care Management Platform of Digital Tools and Social Work   •   Inherited genetic factors may predict the pattern of X chromosome loss in older women   •   76-Year-Old Woman Walking 754 Miles from Chicago to Montgomery for Justice   •   Canada celebrates its top educators for the 30th year, honouring them with the Prime Minister's Awards   •   Parents as Teachers Receives $1.04 Million Grant from Bezos Family Foundation to Advance Life-Saving Maternal Health Initiative   •   Minister Sudds provides an update on Canada's progress on the 2030 Agenda for Sustainable Development   •   Patriot Motors of Sturgeon Bay Partners with Mothers Against Drunk Driving During June   •   Skyway Capital Markets, LLC Advises on the Sale of Aqua ChemPacs, LLC   •   CCM Latino Mortgage Originators Ranked #1 in Northeast and Southwest Regions
Bookmark and Share

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

ELMSFORD, N.Y. , May 22 /Businesswire/ - NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The “pilot” phase of the study is the first component of the broader study.

As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (“RCT”) study of UroShield to further advance clinical evidence of the efficacy of UroShield. This link will take you to the company’s previous press release.

Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “Entering into the pilot phase of the UroShield study at the University of Michigan is an important step towards our goal of applying for permanent FDA clearance or approval for the UroShield product. The experienced and highly accomplished team of researchers at Michigan is studying the impact UroShield may have on reducing urinary tract infections, catheter blockage pain and improving the quality of life of the patients studied. The pilot portion of the study will include up to 30 patients, while the full study is expected to encompass an estimated 300 patients, primarily nursing home residents.”

About NanoVibronix

NanoVibronix, Inc. (Nasdaq: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s PainShield® product is a portable device suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.


STORY TAGS: Research, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Health, University, Science, Education, United States, North America, Michigan, New York, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News